Status:
UNKNOWN
Rapid Breath-hold Quantitative Macromolecular Proton Fraction Imaging for Liver Fibrosis
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Liver Fibrosis
Eligibility:
All Genders
Brief Summary
Chronic liver disease is a major health problem worldwide. Liver fibrosis is a key feature in most chronic liver diseases. When identified early, liver fibrosis may be reversible. Currently, liver bio...
Eligibility Criteria
Inclusion
- Patient group
- patients with histology-proven liver fibrosis, including those with liver fibrosis stage F0, early-stage liver fibrosis (F1-2), and late stage.
- liver fibrosis(F3-4).
- patient aged 18 years old and above.
- Healthy control group
- controls aged 18 years old and above.
Exclusion
- Contraindications to MRI, such as cardiac pacemaker, claustrophobia, pregnancy, metallic implants not suitable for MRI scan.
Key Trial Info
Start Date :
March 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2024
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04429100
Start Date
March 1 2021
End Date
June 30 2024
Last Update
February 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Chinese University of Hong Kong, Prince of Wale Hospital
Hong Kong, Shatin, Hong Kong